Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease

Carlos Stalgis; Parakkal Deepak; Saurabh Mehandru; Jean Frederic Colombel

doi:10.1053/j.gastro.2021.04.068

Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease

Carlos Stalgis, Parakkal Deepak, Saurabh Mehandru, Jean Frederic Colombel

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	394-399
Number of pages	6
Journal	Gastroenterology
Volume	161
Issue number	2
DOIs	https://doi.org/10.1053/j.gastro.2021.04.068
State	Published - Aug 2021

Access to Document

10.1053/j.gastro.2021.04.068

Cite this

@article{14ffba85a9084454a31107b3a919bb52,

title = "Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease",

author = "Carlos Stalgis and Parakkal Deepak and Saurabh Mehandru and Colombel, {Jean Frederic}",

note = "Funding Information: Funding P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology . Funding Information: Funding P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology. Conflicts of interest Parakkal Deepak reports working as a consultant or advisory board with Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, and Arena Pharmaceuticals, and receiving grants from Takeda Pharmaceuticals, Arena Pharmaceuticals, Bristol-Myers Squibb-Celgene, and Boehringer Ingelheim outside the submitted work. Saurabh Mehandru has received investigator initiated grant funding from Takeda Pharma and Genentech and has served a consultant or paid speaker for Takeda Pharma, Genentech, Morphic, and GlaxoSmithKline. Jean-Frederic Colombel reports grants and personal fees from AbbVie, Janssen Pharmaceuticals, and Takeda, and personal fees from Amgen, Allergan, Arena Phramaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Phramaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Landos, Limmatech, Medimmune, Merck, Novartis, OMass, Otsuka, Pfizer, Shire, Tigenix, and VielaBio, outside the submitted work. Carlos Stalgis has worked as a consultant to Amgen and Gilead and has a non-completed contract currently with AstraZeneca.",

year = "2021",

month = aug,

doi = "10.1053/j.gastro.2021.04.068",

language = "English",

volume = "161",

pages = "394--399",

journal = "Gastroenterology",

issn = "0016-5085",

number = "2",

}

TY - JOUR

T1 - Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease

AU - Stalgis, Carlos

AU - Deepak, Parakkal

AU - Mehandru, Saurabh

AU - Colombel, Jean Frederic

N1 - Funding Information: Funding P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology . Funding Information: Funding P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology. Conflicts of interest Parakkal Deepak reports working as a consultant or advisory board with Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, and Arena Pharmaceuticals, and receiving grants from Takeda Pharmaceuticals, Arena Pharmaceuticals, Bristol-Myers Squibb-Celgene, and Boehringer Ingelheim outside the submitted work. Saurabh Mehandru has received investigator initiated grant funding from Takeda Pharma and Genentech and has served a consultant or paid speaker for Takeda Pharma, Genentech, Morphic, and GlaxoSmithKline. Jean-Frederic Colombel reports grants and personal fees from AbbVie, Janssen Pharmaceuticals, and Takeda, and personal fees from Amgen, Allergan, Arena Phramaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Phramaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Landos, Limmatech, Medimmune, Merck, Novartis, OMass, Otsuka, Pfizer, Shire, Tigenix, and VielaBio, outside the submitted work. Carlos Stalgis has worked as a consultant to Amgen and Gilead and has a non-completed contract currently with AstraZeneca.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85108212606&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.04.068

DO - 10.1053/j.gastro.2021.04.068

M3 - Article

C2 - 33961886

AN - SCOPUS:85108212606

SN - 0016-5085

VL - 161

SP - 394

EP - 399

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -

Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease

Access to Document

Other files and links

Cite this